Comments
Drug firm Lupin today said it has received approval from the US health regulator for Hydroxychloroquine Sulfate tablets, which is used to treat malaria. The company has received final approval from the USFDA for its product, which is a generic version of Concordia Pharmaceuticals, Inc’s Plaquenil tablets, Lupin said in a statement.
The drug is indicated for the treatment of malaria and acute and chronic rheumatoid arthritis in adults. According to IQVIA MAT April 2018 data, Hydroxychloroquine Sulfate tablets had annual sales of around $215.3 million in the US. Shares of Lupin ended 0.42 per cent down at Rs 911.95 on the BSE on Monday.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.